Articles by Vladimir Zeldetz in JoVE
En ny metod för att inducera en Depression-liknande beteende hos råttor Vladimir Zeldetz*1, Dmitry Natanel*2, Matthew Boyko2, Alexander Zlotnik2, Honore N. Shiyntum3, Julia Grinshpun2, Dmitry Frank2, Ruslan Kuts2, Evgeni Brotfain2, Jochanan Peiser2 1Department of Emergent Medicine, Soroka University Medical Center, Ben-Gurion University of the Negev, 2Division of Anesthesiology and Critical Care, Soroka Medical Center, Ben-Gurion University of the Negev, 3 Det här protokollet beskriver en ny modell som friska råttor kunde kontrakt depression över en given tid periodthrough smitta av exponering för kronisk oförutsägbara betonade (CUS) råttor.
Other articles by Vladimir Zeldetz on PubMed
Do the Recently Modified Pacemaker Guidelines for Neurocardiogenic Syncope Also Apply to Young Patients? Analysis Based on Five-year Follow-up of Israeli Soldiers with Syncope and a Positive Tilt Test Cardiology. 2004 | Pubmed ID: 15452388 To assess the classification of neurocardiogenic syncope (NCS) as a IIA indication for pacemaker implantation in the recent American College of Cardiology/American Heart Association Task Force on Practice Guidelines/North American Society for Pacing and Electrophysiology guidelines, we performed chart reviews and follow-up interviews in a cohort of 45 consecutive young Israeli soldiers (age 18-24 years) with a history of syncope (mean of 9 prior syncopal episodes) and a positive tilt test treated with drug therapy. Asystole longer than 5 s during tilt testing occurred in 11 patients. Five years later, we found that only 2 patients were still taking medications, only 1 patient (2%) still reported frequent syncopal or near-syncopal episodes and 3 patients (7%) had rare symptoms (no more than one syncopal episode during the past 2 years), while the remaining 40 (89%) were symptom free off medications. Thus, NCS in young patients, even with prolonged asystole during tilt testing, a history of frequent syncopal episodes and other high- risk factors described in the guidelines, is often a self-limiting disorder, perhaps stress related or situational in nature; an overwhelming number of patients become asymptomatic and stop taking medications within 1-2 years. These patients do not require long-term therapy; thus, our data would suggest that the IIA pacing indication for NCS should be restricted to older patients.
The Role of Icatibant-the B2 Bradykinin Receptor Antagonist-in Life-threatening Laryngeal Angioedema in the ED The American Journal of Emergency Medicine. Mar, 2015 | Pubmed ID: 25241359 Angioedema is a localized, sudden, transient, and often recurrent swelling of the deeper layers of the skin or mucosa with no epidermal component. It is caused by vasoactive substances that produce a transient increase in endothelial permeability. Angioedema involving the laryngeal components is a life-threatening situation for the patient,and it is a challenge for the emergency medicine physician to rapidly achieve a safety airway. Most cases of laryngeal angioedema are induced by histamine release; but 10% are bradykinin induced, which does not respond to the conventional algorithm of treating allergic induced angioedema. We present a case report of an angiotensin converting enzyme (ACE) inhibitor–induced laryngeal angioedema alleviated only after treatment with the new bradykinin receptor inhibitor medication icatibant which was licensed only for use in hereditary angioedema. We reviewed the literature for the use of icatibant in acquired drug-induced angioedema; and because of the similar pathogenesis between the hereditary angioedema and the ACE inhibitor–induced angioedema,we propose an algorithm for careful use of icatibantin life-threatening angioedema in the emergency department.
Blood Glutamate Reducing Effect of Hemofiltration in Critically Ill Patients Neurotoxicity Research. Feb, 2018 | Pubmed ID: 28836163 Glutamate toxicity plays a well-established role in secondary brain damage following acute and chronic brain insults. Previous studies have demonstrated the efficacy of hemodialysis and peritoneal dialysis in reducing blood glutamate levels. However, these methods are not viable options for hemodynamically unstable patients. Given more favorable hemodynamics, longer treatment, and less needed anticoagulation, we investigated whether hemofiltration could be effective in lowering blood glutamate levels. Blood samples were taken from 10 critically ill patients immediately before initiation of hemofiltration and after 1, 2, 4, 6, and 12 h, for a total of 6 blood samples. Samples were sent for determination of glutamate, glutamate oxaloacetate transaminase (GOT), glutamate pyruvate transaminase (GPT), hemoglobin, hematocrit, urea, creatinine, glucose, sodium, potassium, platelet, and white blood cell (WBC) levels. There was a statistically significant reduction in blood glutamate levels at all time points compared to baseline levels. There was no difference in levels of GOT or GPT. Hemofiltration can be a promising method of reducing blood glutamate levels, especially in critically ill patients where hemodialysis and peritoneal dialysis may be contraindicated.